Top Stories
The AI biotech secured ex-China rights to Alphamab's TROP2/HER3 ADC in a deal worth up to $2.2 billion and partnered with AstraZeneca on a breast cancer PROTAC programme.
With its fully automated bioanalysis platform, Dash can return preclinical sample results in days, not months.
Cloud breach exposed proprietary information as the drugmaker launches an investigation.
The multi-year study will test whether OhmX can give labs a clearer view of structural variants in AML and MDS without having to piece together results from multiple tests.
Researchers traced the assay's signals to liver, vascular and immune cells, suggesting it could capture both tumour DNA and the body's response to cancer.
Conference News
University of Colorado Anschutz-led study shows automated oxygen system increases time in target oxygen range and reduces clinician workload compared with standard careAURORA, Colo., Aug. 3, 2026 /PRN...
Following the introduction of Invenia™ ABUS Prime at the Society of Breast Imaging Annual Symposium, the installation at BeSound in Los Angeles marks one of the first in the U.S., expanding access to ...
Company will present two scientific posters examining the operational and readiness applications of its tAN® platform, marking a key step in Spark's expansion into the military-ready and first respond...
Second Quarter Revenue Growth of 52% to $132 MillionRaises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 MillionBRISBANE, Calif.--(BUSINE...
Second quarter 2026 revenue growth of 44% driven by strong performance in Oncology and ScreeningRaises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38%PALO ALTO, Cali...
